In this Urology Times supplement, we’ll take a look at the science behind Rezūm, the nuts and bolts of the procedure, what sort of short- and long-term outcomes patients can expect following the procedure, and ways that urologists can educate their patients about this new technology.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.